CN115317543B

CN115317543B - Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof

Info

Publication number: CN115317543B
Application number: CN202211109828.1A
Authority: CN
Inventors: 高鹏飞; 陈漫漫; 徐月妹; 肖茜
Original assignee: Jinshan Hospital Affiliated To Fudan University Shanghai Jinshan Eye Disease Prevention And Treatment Institute Shanghai Jinshan Nuclear And Chemical Injury Emergency Treatment Center
Current assignee: Jinshan Hospital Affiliated To Fudan University Shanghai Jinshan Eye Disease Prevention And Treatment Institute Shanghai Jinshan Nuclear And Chemical Injury Emergency Treatment Center
Priority date: 2022-09-13
Filing date: 2022-09-13
Publication date: 2023-05-23
Anticipated expiration: 2042-09-13
Also published as: CN115317543A

Abstract

The invention relates to a traditional Chinese medicine composition for treating liver cancer cachexia, which is prepared from the following raw materials in parts by weight: 16-24 parts of kiwi fruit juice, 6-14 parts of red sage root, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae. The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating liver cancer cachexia. The invention has the advantages that the invention exactly coincides with the difficult point of 'deficiency without being supplemented' of cancer cachexia treatment, can improve the anorexia and the hypodynamia of patients suffering from liver cancer cachexia, has no toxic or side effect and has wide clinical application prospect for treating the liver cancer cachexia state.

Description

Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof

Technical Field

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating liver cancer cachexia and application thereof.

Background

Cachexia is one of the leading causes of death in cancer patients, and it has been shown from international clinical epidemiological studies that cachexia occurs in approximately 40% -80% of cancer patients in advanced stages, leading to death in the patient. Patients with cachexia are clinically manifested as progressive decline in body mass. And the liver cancer patients are easy to develop cachexia, and the main reason is that liver cancer cells are easy to secrete various inflammatory factors, and the inflammatory factors are released into blood in a large amount. While the liver is the central organ regulating the metabolism of the body. The main means for treating cancer clinically at present include chemotherapy, radiotherapy, targeted drug application and other means, and the aim of delaying the disease progress of a patient and prolonging the survival period of the patient is achieved by inhibiting or killing cancer cells. However, these approaches are not effective in delaying the onset of cachexia.

The cancer cachexia is often accompanied with anorexia, and compared with western medicines, the traditional Chinese medicine has the advantages of overall regulation, less side effects and definite curative effect in the aspect of treating anorexia. There is no disease name of cancer cachexia in traditional Chinese medicine, but many symptoms are described similar to cachexia, and the condition of "the condition is very similar to advanced liver cancer combined with cachexia" in the "Su-Yu machine Zhen Zong Lun" has the symptoms of dry large bones, large meat sinking down, fullness in chest, dyspnea, pneumatic shape and period June death ". The etiology of the cancer cachexia disease is considered by the traditional Chinese medicine: the deficiency with the middle-jiao being filled with excess is the coexistence of qi and blood deficiency of the whole body, viscera function under and excess evil of local tumor, one of the main nuclear heart disease mechanisms is serious decline of blood biochemical function in postnatal weather, the source of acquired biochemical tonification is one of the important therapeutic principles for treating the disease, and the deficiency of long-term disease, kidney, spleen and kidney is also an important pathogenesis of the disease. Aiming at the cancer cachexia anorexia clinically, the medicine mainly takes qi-tonifying and yin-nourishing, spleen-activating and stomach-invigorating and digestion-promoting functions, spleen-stomach-tonifying and the like as main treatment rules, and has better clinical effects when being used for regulating qi or activating blood circulation to dissipate blood stasis. How cancer cachexia is tonic to promote healing, while "deficiency is not tonic" is a bottleneck in clinical treatment.

Another patent CN102772732a before the applicant discloses a pharmaceutical composition for treating chronic liver disease, which is prepared from the following raw materials in parts by weight: 20-60 parts of kiwi fruit juice, 10-30 parts of red sage root, 5-15 parts of bighead atractylodes rhizome, 4-12 parts of epimedium herb, 4-12 parts of poria cocos, 2-6 parts of radix bupleuri, 5-15 parts of schisandra chinensis, 1.5-4.5 parts of white cardamom, 2.5-7.5 parts of dried orange peel and 5-15 parts of radix pseudostellariae, but the preparation process and the medicinal application are different from those of the invention, the medicinal taste is reduced on the basis of the invention, the medicament aims at liver cancer cachexia, and the medicinal application is not disclosed or provided in the patent. Meanwhile, the subject group of the inventor is liver-protecting prescription 919 particles prepared based on the pharmaceutical composition in the application, and the prescription is a traditional Chinese medicine compound preparation formed by combining clinical personal experience with folk prescription. Clinical and basic researches for over 30 years prove that the composition has definite effects of protecting liver, reducing enzyme, resisting hepatitis B virus, resisting liver steatosis and resisting liver fibrosis. According to the two methods of tonifying and eliminating in the eight methods of traditional Chinese medicine, the compatibility of the liver-protecting prescription 919 particles is used for tonifying and eliminating, activating blood and regulating qi, and meanwhile, the tonifying effect is achieved, the anorexia and the hypodynamia of cancer cachexia patients can be improved, and no toxic or side effect is caused. The prescription of the prescription is exactly matched with the difficult point of 'deficiency without compensation' of the treatment of the liver cancer cachexia, and the prescription is considered to have wide clinical application prospect in the treatment of the liver cancer cachexia state.

At present, the report of the invention for treating liver cancer cachexia is not yet reported.

Disclosure of Invention

The invention aims at providing a traditional Chinese medicine composition for treating liver cancer cachexia, aiming at the defects in the prior art.

The second object of the invention is to provide a use of the pharmaceutical composition for treating liver cancer cachexia.

In order to achieve the first object, the invention adopts the following technical scheme:

a traditional Chinese medicine composition for treating liver cancer cachexia is prepared from the following raw materials in parts by weight:

16-24 parts of kiwi fruit juice, 6-14 parts of red sage root, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae.

As a preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:

18-22 parts of kiwi fruit juice, 8-12 parts of red sage root, 4-6 parts of bighead atractylodes rhizome, 3-5 parts of epimedium herb, 3-5 parts of poria cocos, 1-3 parts of radix bupleuri, 4-6 parts of schisandra chinensis and 4-6 parts of radix pseudostellariae.

More preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:

20 parts of kiwi fruit juice, 10 parts of red sage root, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of radix bupleuri, 5 parts of shizandra berry and 5 parts of radix pseudostellariae.

The preparation method of the pharmaceutical composition comprises the following steps:

(a) Placing fructus Schisandrae, bupleuri radix, and Atractylodis rhizoma into a distillation pot, adding three times of water, distilling, collecting distilled volatile oil solution, and sealing and preserving;

(b) Adding water into the distilled residues, decocting for one hour, standing for ten hours, filtering to obtain juice, and collecting and concentrating;

(c) Putting the red sage root, the radix pseudostellariae, the epimedium herb, the poria cocos and the four medicines into a decocting pot, adding water for boiling twice, keeping boiling for one hour, naturally cooling, filtering to obtain juice, mixing the two decoctions, standing for six hours, filtering to obtain juice, and collecting and mixing to prepare the Chinese medicinal composition;

(d) Mixing the filtrate obtained in the step (b) and the filtrate obtained in the step (c), and concentrating the mixture to a specific gravity of 1 by adopting a low-temperature and pressure-reducing concentration method: 1, mixing the filtrate with 20/10 of kiwi fruit juice, adding the volatile oil solution obtained in the step (a) and distilled water, fully stirring to obtain thick extract, granulating, drying and finishing.

As a preferred example, the dosage form of the traditional Chinese medicine composition is granules.

In order to achieve the second purpose, the invention adopts the following technical scheme:

the application of the traditional Chinese medicine composition in preparing medicines for treating liver cancer cachexia.

The compatibility of the traditional Chinese medicine composition is as follows:

in the formula, kiwi fruits are taken as monarch drugs, the 'materia medica outline mesh' is 'sour, sweet, cold and nontoxic', enters liver, spleen, kidney, heart and lung channels, stops sudden thirst and relieves dysphoria heat. According to the traditional Chinese medicine theory of 'seeing liver disease, knowing liver and transmitting spleen, when spleen is first strengthened', radix pseudostellariae, bighead atractylodes rhizome, poria cocos and spleen strengthening and stomach are taken as ministerial drugs, liver and spleen long-term diseases affect yin and yang of kidney, epimedium is taken as adjuvant drug, liver body yin is used for yang, radix salviae miltiorrhizae is used for resisting four things soup, blood is enriched for activating blood, and the medicine is also taken as adjuvant drug, and radix bupleuri and shizandra berry are taken as guiding drugs for astringing one. The recipe is prepared by combining the methods of nourishing liver, strengthening spleen, nourishing kidney, harmonizing stomach, regulating vital energy, promoting blood circulation and the like in one furnace.

Detailed Description

The invention is further described below in conjunction with the detailed description. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Further, it is understood that various changes and modifications of the present invention may be made by those skilled in the art after reading the description of the present invention, and such equivalents are intended to fall within the scope of the claims appended hereto.

Example 1 pharmaceutical composition (I)

Example 2 pharmaceutical composition (II)

20 parts of kiwi fruit juice, 8 parts of red sage root, 6 parts of bighead atractylodes rhizome, 2 parts of epimedium herb, 6 parts of poria cocos, 2 parts of radix bupleuri, 4 parts of shizandra berry and 6 parts of radix pseudostellariae.

EXAMPLE 3 pharmaceutical composition (III)

18 parts of kiwi fruit juice, 12 parts of red sage root, 3 parts of bighead atractylodes rhizome, 6 parts of epimedium herb, 4 parts of poria cocos, 1 part of bupleurum, 6 parts of shizandra berry and 3 parts of radix pseudostellariae.

Example 4 pharmaceutical composition (IV)

22 parts of kiwi fruit juice, 6 parts of red sage root, 7 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 3 parts of poria cocos, 3 parts of radix bupleuri, 3 parts of shizandra berry and 7 parts of radix pseudostellariae.

Example 5 composition (five)

16 parts of kiwi fruit juice, 14 parts of red sage root, 5 parts of bighead atractylodes rhizome, 3 parts of epimedium herb, 5 parts of poria cocos, 1 part of bupleurum, 7 parts of shizandra berry and 5 parts of radix pseudostellariae.

Example 6 pharmaceutical composition (six)

24 parts of kiwi fruit juice, 10 parts of red sage root, 4 parts of bighead atractylodes rhizome, 5 parts of epimedium herb, 2 parts of poria cocos, 4 parts of radix bupleuri, 5 parts of shizandra berry and 4 parts of radix pseudostellariae.

Example 7 pharmaceutical composition for treating liver cancer cachexia (seven)

20 parts of kiwi fruit juice, 12 parts of red sage root, 3 parts of bighead atractylodes rhizome, 6 parts of epimedium herb, 4 parts of poria cocos, 1 part of bupleurum, 6 parts of shizandra berry and 3 parts of radix pseudostellariae.

EXAMPLE 8 pharmaceutical composition (eight)

18 parts of kiwi fruit juice, 6 parts of red sage root, 7 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 3 parts of poria cocos, 3 parts of radix bupleuri, 3 parts of shizandra berry and 7 parts of radix pseudostellariae.

Example 9 pharmaceutical composition (nine)

22 parts of kiwi fruit juice, 14 parts of red sage root, 5 parts of bighead atractylodes rhizome, 3 parts of epimedium herb, 5 parts of poria cocos, 1 part of bupleurum, 7 parts of shizandra berry and 5 parts of radix pseudostellariae.

EXAMPLE 10 pharmaceutical composition (ten)

16 parts of kiwi fruit juice, 10 parts of red sage root, 4 parts of bighead atractylodes rhizome, 5 parts of epimedium herb, 2 parts of poria cocos, 4 parts of radix bupleuri, 5 parts of shizandra berry and 4 parts of radix pseudostellariae.

Example 11 pharmaceutical composition (eleven)

24 parts of kiwi fruit juice, 8 parts of red sage root, 6 parts of bighead atractylodes rhizome, 2 parts of epimedium herb, 2 parts of poria cocos, 2 parts of radix bupleuri, 4 parts of shizandra berry and 6 parts of radix pseudostellariae.

EXAMPLE 12 preparation of pharmaceutical compositions

(a) Placing fructus Schisandrae, bupleuri radix, and Atractylodis rhizoma into a distillation pot, adding three times of water, distilling, collecting distilled volatile oil solution, and sealing and storing in a container. Adding water into the distilled residues, decocting for one hour, standing for ten hours, filtering to obtain juice, and collecting and concentrating.

(b) Putting the red sage root, the radix pseudostellariae, the epimedium herb, the poria cocos and the four medicines into a decoction pot, adding water for boiling twice, keeping boiling for one hour, naturally cooling, filtering to obtain juice, combining the two decoctions, standing for six hours, filtering to obtain juice, and collecting and mixing.

(c) Mixing the filtrate obtained in the step (b) and the filtrate obtained in the step (c), and concentrating the mixture to a specific gravity of 1 by adopting a low-temperature and pressure-reducing concentration method: 1, mixing the filtrate with 20/10 of kiwi fruit juice, adding the volatile oil solution obtained in the step (a) and distilled water, fully stirring to obtain thick extract, granulating, drying and finishing.

Example 13 animal experiments

1 Material

1.1 laboratory animals

90 male and female BALB/c mice of 7 weeks old were purchased from Shanghai Ji Hui laboratory animal feeding Co., ltd. [ SCXK (Shanghai) 2017-0012] and weighing 18-28g, and placed in Shanghai public health clinical center animal houses (SPF grade). Every 5 mice were housed in a cage (300X 200X 120 mm) of plastic wood-covered cage. The room was kept at standard conditions of constant temperature (23.+ -. 3 ℃), constant humidity (50%.+ -. 10%), illumination for 12 hours (8:00-20:00). All mice were free to obtain sterile food and water throughout the experiment, except for the binding time.

1.2 instruments and reagents

1.2.1 reagents

Propranolol hydrochloride (content: 99.4% of Changzhou yabang pharmaceutical Co., ltd.); 9.4% Fetal Bovine Serum (FBS), pancreatin, blue chain mycin (Gibco Co., U.S.A.); modified RPMI 1640 medium (HyClone, USA); coomassie protein assay kit, plasma Creatine Kinase (CK) assay kit (institute of bioengineering, built in south kyo); the pro-inflammatory factor interleukin-1 beta (1L-beta), interleukin-6 (1L-6), tumor necrosis factor-alpha (TNF-alpha) enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Eikesai biologicals Co., ltd.).

1.2.2 instruments

Eclipse Ties type inverted microscope (Nikon Corp.); SUNRISE type microplate reader (Tecan, switzerland); AU2700 full automatic biochemical analyzer (Beckman Coulter company, usa); CM 3050 type frozen microtome (Leica company, germany); galaxy171R type cell incubator, 5430R type desktop cryocentrifuge (Eppendorf, germany).

2 protocol

2.1 animal Molding

Resuscitate liver cancer cell line HepG2 in cell culture medium (modified RPMI 1640 medium, 10% FBS,100 mg/L-streptomycin and 1/10) ⁵ U/L-penicillin) to a density of 1X 10 ⁵ Inoculating to 100mm culture dish, placing into 5% CO at 37deg.C ₂ Culturing in an incubator. After 0.05% pancreatin is added to digest the whole culture dish when the cells grow, the cells are collected and prepared into 1X 10 with physiological saline ⁷ 60 BALB/C inbred mice were injected into the subcutaneous region of the right forelimb axilla and the mice were kept on feeding. After 4 weeks of feeding, animals with tumor growth were selected, and after anesthesia and sterilization, the grown tumor tissue was removed. Cutting tumor into 1.0mm at 4deg.C ³ Resistant to left and right tissue pieces. After washing the tissue pieces with 0.01% Phosphate Buffered Saline (PBS), the tissue pieces were re-implanted into the right forelimb axilla of BALB/C inbred mice. When the mice are obviously emaciated, have anorexia, weakness and failure, the body mass is reduced to be significantly different from that of normal groups, the mice enter a cachexia state, which indicates that the model preparation is successful. After 28d, when the tumor appearance grew and the quality of the mice began to decrease, group dosing was started.

2.2 grouping and administration

The mice successfully molded are randomly selected to be 60 groups, 10 mice in each group are respectively in a male half and a female half, the mice are respectively a first group, a second group, a first control group, a second control group, a model group and a western medicine group, 10 mice which are not molded are selected to be blank groups, and the mice are continuously dosed for 10 days according to the following mode:

the first group of the invention: the crude drugs were weighed according to the parts by weight described in example 1, and the drugs were prepared according to example 12, and 20mL/kg of the granular drug solution (distilled water dissolution, 1.5 g/mL) was administered daily.

The invention is two: the crude drugs were weighed according to the parts by weight described in example 2, and the drugs were prepared according to example 12, and 20mL/kg of the granular drug solution (distilled water dissolution, 1.5 g/mL) was administered daily.

Control group one: according to the weight proportion, 20 parts of kiwi fruit juice, 10 parts of red sage root, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of radix bupleuri, 5 parts of Chinese magnoliavine fruit, 1.5 parts of white cardamon, 2.5 parts of dried orange peel and 5 parts of radix pseudostellariae are weighed, the medicine is prepared according to the example 12, and 20mL/kg of granular medicine solution (distilled water is dissolved, 1.5 g/mL) is infused every day.

Control group two: weighing 20 parts of kiwi fruit juice, 10 parts of red sage root, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of bupleurum, 5 parts of dark plum and 5 parts of American ginseng according to the weight ratio. The drug was prepared as in example 12, and 20mL/kg of the granular drug solution (dissolved in distilled water, 1.5 g/mL) was administered daily.

Western medicine group: propranolol is taken orally at a dosage of 3mg/kg per day.

Model group: the stomach was irrigated with 20mL/kg physiological saline daily.

Blank group: the stomach was irrigated with 20mL/kg physiological saline daily.

2.3 detection index

2.3.1 assessment of mouse body Mass

And the body mass of the mice after molding is measured, and the state of the mice under cachexia is accurately reflected.

2.3.2 ELISA (enzyme-Linked immuno sorbent assay) for detecting levels of CK and proinflammatory factors in plasma of mice

Each group of mice was anesthetized with sodium pentobarbital (40 mg/kg), the abdominal aorta was bled, heparin anticoagulated, and the supernatant plasma was transferred to a new 1.5mL centrifuge tube by centrifugation at 3000r/min for 10min and stored at-20 ℃. The levels of CK and 1L-1 beta, 1L-6, TNF-alpha were determined separately using ELISA kits according to instructions.

3 statistical analysis

SPSS 23.0 statistical software is adopted for data processing, the experimental result represents the difference between different groups by mean ± standard error (X+ -SEM), one-way anova with T-test is adopted for statistical analysis, and P <0.05 is taken as the difference to have statistical significance.

Results 4 results

4.1 Effect on the quality of liver cancer cachexia mice

The quality of mice in the cachexia model group was significantly reduced compared to the blank group (p < 0.001); compared with the model group, the group and western medicine group control group can obviously delay the action of reducing the quality of the liver cancer cachexia mice (p is less than 0.05); wherein the effect of the first and second groups of the invention is better than that of the first and second control groups (p < 0.05); the first group of the present invention was not significantly different from the western group, as shown in table 1.

TABLE 1 influence of Chinese medicinal composition on quality of liver cancer cachexia mice

n＝70)

Group of	n (example)	Body mass/g
			The invention is one of	10	24.19±1.96 ^2,3)
The invention is two	10	23.09±2.55 ^2,3)
			Control group one	10	22.39±1.881 ²⁾
Control group two	10	22.61±1.89 ²⁾
			Western medicine group	10	24.08±2.10 ²⁾
Model group	10	21.95±2.19 ¹⁾
			Blank group	10	25.51±1.14

Note that: comparison with blank group ¹⁾ (p<0.001 A) is provided; comparison with model group ²⁾ (p<0.05 A) is provided; comparison with the control group ³⁾ (p<0.05)

4.2 Effect on the levels of mouse skeletal muscle catabolite plasma CK

Plasma creatine kinase levels were significantly increased (P < 0.01) in the cachexia model group compared to the blank group; compared with the model group, the plasma creatine kinase level of the group, western medicine group and control group is obviously reduced (P < 0.05); compared with the control group, the blood creatine kinase level of the group is further reduced (P < 0.01), which indicates that the muscle degradation degree is obviously reduced; whereas the inhibition level of the present group one was significantly higher than that of the present group two (P < 0.05); the inhibition level of the first invention was not significantly different from that of the western medicine group, as shown in table 2.

TABLE 2 Effect of Chinese medicinal composition on creatine kinase levels in plasma of cachexia mice

n＝70)

Group of	n (example)	CK/UL ^-1
			The invention is one of	10	69.31±12.28 ^2,3,4)
The invention is two	10	75.73±11.05 ^2.3)
			Control group one	10	87.12±9.66 ²⁾
Control group two	10	83.55±14.14 ²⁾
			Western medicine group	10	72.31±11.30 ²⁾
Model group	10	137.29±21.42 ¹⁾
			Blank group	10	66.21±11.72

Note that: comparison with blank group ¹⁾ (p<0.01 A) is provided; comparison with model group ²⁾ (p<0.05 A) is provided; comparison with the control group ³⁾ (p<0.01 A) is provided; comparison with the second inventive group ⁴⁾ (p<0.05)

4.3 inhibition of secretion levels of 1L-1 beta, 1L-6, TNF-alpha in plasma of cachectic mice

Compared with a blank group, the level of 1L-1 beta, 1L-6 and TNF-alpha in the plasma of the mice in the cachexia model group is significantly increased (P < 0.001); compared with the model group, the 1L-1 beta, 1L-6 and TNF-alpha levels of the group, western medicine group and control group are obviously reduced (P < 0.05); compared with the control group, the group has obvious inhibition effect (P < 0.05); wherein the level of 1L-1 beta of the present group one is significantly lower than that of the western group (P < 0.05); the invention is significantly lower than the control group (P < 0.05), (P < 0.01); wherein 1L-6 of inventive group one is significantly lower than western and inventive group two (P < 0.05); and TNF- α of inventive group one was significantly lower than that of inventive group two (P < 0.05), see table 3.

TABLE 3 Effect of Chinese medicinal composition on 1L-1 beta, 1L-6, TNF-alpha levels in plasma of cachexia mice

n＝70)

Group of	n (example)	1L-1β	1L-6	TNF-α
					The invention is one of	10	66.43±17.28 ^2,3,5)	618.92±128.59 ^2,4,5,6)	644.18±144.04 ^2,3,6)
The invention is two	10	72.41±12.42 ^2,3)	738.88±47.04 ^2,3)	748.18±93.09 ^2,3)
					Control group one	10	84.51±10.15 ²⁾	845.99±86.45 ²⁾	849.84±104.73 ²⁾
Control group two	10	81.87±13.54 ²⁾	822.67±130.13 ²⁾	843.70±192.10 ²⁾
					Western medicine group	10	79.88±9.44 ²⁾	760.89±115.63 ²⁾	700.53±87.08 ²⁾
Model group	10	107.89±15.93 ¹⁾	1007.24±193.86 ¹⁾	979.28±133.70 ¹⁾
					Blank group	10	55.21±11.85	548.93±81.97	494.18±93.04

Note that: comparison with blank group ¹⁾ (p<0.001 A) is provided; comparison with model group ²⁾ (p<0.05 A) is provided; comparison with the control group ³⁾ (p<0.05)， ⁴⁾ p<0.001 A) is provided; comparison with Western medicine group ⁵⁾ (p<0.05 A) is provided; comparison with the second inventive group ⁶⁾ (p<0.05)

In summary, the drugs of the invention, western medicine group and control group can inhibit the cachexia progress of the mouse cachexia model induced by human liver cancer cell line Hep G2 to different degrees, the drug inhibition effect of the invention group is superior to the control group, and overall the effect of the invention group I is most prominent.

The foregoing is merely a preferred embodiment of the present invention, and it should be noted that modifications and additions may be made to those skilled in the art without departing from the method of the present invention, which modifications and additions are also to be considered as within the scope of the present invention.

Claims

1. The traditional Chinese medicine composition for treating liver cancer cachexia is characterized by being prepared from the following raw materials in parts by weight: 16-24 parts of kiwi fruit juice, 6-14 parts of red sage root, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae.

2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 18-22 parts of kiwi fruit juice, 8-12 parts of red sage root, 4-6 parts of bighead atractylodes rhizome, 3-5 parts of epimedium herb, 3-5 parts of poria cocos, 1-3 parts of radix bupleuri, 4-6 parts of schisandra chinensis and 4-6 parts of radix pseudostellariae.

3. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20 parts of kiwi fruit juice, 10 parts of red sage root, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of radix bupleuri, 5 parts of shizandra berry and 5 parts of radix pseudostellariae.

4. Use of a Chinese medicinal composition according to any one of claims 1-3 in the preparation of a medicament for treating liver cancer cachexia.